Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:25822/feed
Oncology
Vol. 3, Issue 2, 2016November 16, 2015 EDT

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy

November McGarvey, Hairong Xu,
chemotherapy-induced anemiaerythropoiesis-stimulating agentbudget impact
Copyright Logoccby-4.0 • https://doi.org/10.36469/9836
Photo by Hush Naidoo on Unsplash
JHEOR
1.
McGarvey N, Xu H. Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy. JHEOR. 2015;3(2):214-223. doi:10.36469/​9836
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system